Highlights  Activation of CB2R improved the novel object recognition memory, however, had no effect on spatial memory in APP/PS1 mice.  Activation of CB2R had no effect on amyloid plaque burden in the cortex and hippocampus of APP/PS1 mice.
Alzheimer's disease (AD) is one of the most common age-dependent neurodegenerative diseases in humans [1] . Patients suffering from AD present a progressive decline of life quality, especially in cognitive abilities, which include increased incidence of wandering, a barrier in communication skills, and the inability to recognize familiar faces [2, 3] . Previous studies showed that the pathological features of AD are excessive extracellular plaque deposition formed by amyloid protein, intracellular neurofibrillary tangles formed by hyperphosphorylated tau protein, and selective loss of vulnerable neurons, particularly in cognitive function-associated brain regions such as the cortex and hippocampus [4] .
Chronic neuroinflammation, characterized by the activation of astrocyte and microglia, release of various inflammatory mediators and neurotoxic free radicals, and chronic progressive neuronal damage, may play a crucial role in AD progression [5, 6] .
Previous trials showed that anti-inflammatory drugs like minocycline or NSAIDS show benefits to AD patients in clinical practice, thus, modulating neuroinflammation has been an attractive method in treating AD and currently receives significant attention [7] .
Cannabinoid receptor 2 (CB2R), a well-characterized cannabinoid receptor A C C E P T E D M A N U S C R I P T subtype in the endocannabinoid system, has been reported to be a potential pharmacologic target for neuroinflammation-related diseases, including AD, ischemic stroke, amyotrophic lateral sclerosis, Parkinson and Huntington's disease [8] [9] [10] [11] .
Researches revealed a relatively lower expression of CB2R located at CNS neurons, with the main expression of CB2R at the activated microglia at inflammation conditions [12] [13] [14] . Evidences showed that the surround of senile plaque recruit microglia which highly expressed CB2R in autopsies of AD transgenic mice and patients [15, 16 ].
Moreover, CB2R expression level is positively correlated with AD patients' plaque burdens and cognitive dysfunction severity [17, 18] . CB2R activation by synthetic or endogenous CB2R agonists has demonstrated neuroprotective and pro-cognitive functions by mediating microglia activation [8, [19] [20] [21] .
Activated microglia has two phenotypes: M1 expressing pro-inflammatory factors and M2 expressing anti-inflammatory mediators [7, 22] . Microglia may play opposite roles in specific conditions of disease stage and affected brain regions, which are highly related to microenvironment [7] . Furthermore, the conversion of microglial phenotype from M1 to M2 strongly correlates with CB2R in germinal matrix hemorrhage [23] .
Additionally, activation or knockout of CB2R influences the neurogenesis and neural plasticity, both of which are associated with cognition and memory [24] [25] [26] [27] [28] .
Studies support that CB2R activation reduces microglia-mediated neuroinflammation and ameliorates cognitive dysfunction in AD-model mice [8, [19] [20] [21] 28] . Meanwhile, knockout of CB2R in mice can mediate microglia activation, promoting AD progression [17, 29, 30] . However, the underlying mechanism of CB2R on neuroinflammation in AD remains unknown. Thus, the present study explored the effects of CB2R agonist treatment on novel object recognition and spatial memory in AD mice.
Materials and methods

Animals
Transgenic APP/PS1 mice (APPswe and PS1dE9) and wild-type (WT) C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, Maine, USA) and bred in standard housing conditions with free access to distilled water and food. All mice
were genotyped by PCR using tail tissue DNA. All experiments were approved by the Ethical Committee of the Fourth Hospital of Hebei Medical University.
Pharmacological treatment
Selective CB2R agonist JWH-015 was purchased from Sigma Aldrich (St. Louis, MI). Before administration, JWH-015 was diluted in saline with 1% DMSO and 1% Tween 80. Eight-month-old male APP/PS1 mice and WT littermates were randomly divided into three groups (n=15): WT+vehicle (VEH), APP/PS1+VEH, APP/PS1+JWH-015. Each morning for 8 weeks, animals were injected with VEH or JWH-015 at a dose of 0.5 mg/kg intra-peritoneally in a volume of 20 ml/kg.
Novel object recognition test (NOR)
NOR was performed as previously described [20] . The test was conducted over 3 d by an investigator blinded to the treatment groups. On d 1, mice were habituated to the empty arena for 20 min. On d 2, mice were returned to the arena with two identical objects for 6min. On d 3, one of two familiar objects was replaced by a novel one, with different shape, color, and material. Mice explored the arena for 6 min, and total time spent exploring each object was recorded. Exploration of an object was defined as nosing and sniffing at it at a distance less than 2cm.Data was presented as recognition index (RI), which was calculated as the time spent exploring the novel object divided by the total time spent exploring the two objects.
Morris water maze test (MWM)
Spatial learning and memory of mice was assessed using MWM [31] Swimming speed was recorded. During the spatial probe test (d 6), the escape platform was removed. All animals were placed into the pool from the quadrant opposite to the one previously used and were allowed to swim freely for 60 s. The number of former platform crossings and time spent in target quarter were analyzed.
Congo red staining
Congo red staining was conducted according to the manufacture's protocol (Sigma Aldrich, St. Louis, MI). Briefly, 20μm thick coronal sections were rehydrated and incubated in alkaline sodium chloride solution for 20 min at room temperature. NaOH solution was added to freshly prepared and filtered Congo red solution, then sections were stained in this solution for 20 min at room temperature followed by Mayer's hematoxlyin counterstaining (Sigma-Aldrich, St. Louis, MI).
Digital images of the hippocampus and overlying cortex of Congo red stained sections were taken using an Olympus VS120 microscope at 10× magnification.
Quantification of amyloid plaque burden was performed in a blinded manner by manually counting the number of Congo red positive plaque in 3 coronal sections and estimating average number of plaque in each area per mouse.
Immunofluorescence staining
A cohort of mice (n=5 per group) were deeply anesthetized and transcardially perfused with 4C phosphate buffer solution (PBS) followed by 4% paraformaldehyde in PBS. Brains tissues were removed rapidly, postfixed in 4% paraformaldehyde overnight and then transferred into 30% sucrose in PBS for 3 d followed by continuous serial 20μm coronal frozen sections in Leica cryostat.
After antigen retrieval with microwave in citrate for 15min, coronal sections were subsequently incubated with 3% bovine serum albumin and 0.3% Triton X-100 PBS at room temperature for tissue permeabilization and sheltering unspecific binding sites. Fluorescent examination of Iba1-labeled microglia was performed using a Nikon Eclipse Ni microscope coupled with a digital color camera (Jenoptik I Optical Systems, Germany) at a fixed setting. Representative pictures in the hippocampus and overlying cortex were taken at 10× magnification in a blind manner and integrated optical density per slice area was measured using image pro primer 3D software from 5-6 sections per group.
RNA extraction and Real-Time PCR analysis
Samples (n=5 per group) of cortex and hippocampus were dissected on an ice-cold glass dish, placed into RNAfixer solution (Biomed, Beijing, China) immediately and then stored at -20C until RNA isolation. Total RNA was extracted using the RNeasy Mini kit according to the manufacturer's instructions (Qiagen, USA). Quality and concentration of RNA samples were checked with the Nanodrop 2000 spectrophotometer (Thermo, USA).
Reverse transcription for cDNA was undertaken following the instructions of the ReverTra Ace qPCR RT Master Mix with gDNA Remover kit (Toybo, Osaka, Japan).
Briefly, 500ng RNA was denatured for 5 min at 65C, and then reverse transcribed in 10-μl reaction volume following cycling conditions: 37C for 15min, 50C for 5min and 98C for 5min. After reverse transcription, cDNA was stored at 4C.
Real-time PCR analysis was performed using the Fast Start Essential DNA Green Master kit (Roche) on Roche LightCycler. The primers were synthesized by Invitrogen company and listed in Table1，including M1 microglia markers (IL-6, TNF-α，iNOS), M2 microglia marker (Ym1/2) and housekeeping gene (GAPDH). A 50ng quantity of cDNA was used per reaction and amplification conditions were as follows: 95C for 10 min, 95C for 10s and 60C for 1min for 45 cycles. The mRNA expression levels were normalized against GAPDH and presented as 2 -△△ ct with WT-VEH mice as control.
Golgi staining and dendritic analysis
Golgi staining was done using a FD Rapid Golgistain Kit according to
manufacturer's instructions (FD NeuroTechnologies, USA). Briefly, 5 mice brains per group were impregnated in a mixture of solution A and B (1:1) at room temperature for 2 weeks in the dark. Then tissues were transferred into solution C and stored at 4C for 7 d in darkness. The brains were sliced into 100μm thick coronal sections at levels of cortex and hippocampus with a cryostat at -20C (Leica, Germany), and mounted on clean gelatin-coated microscope slides followed by natural drying at room temperature.
Sections were rehydrated, stained with a mixture composed of solution D, E and distilled H2O (1:1:2 ratio) for 10 min and dehydrated with graded ethanol. Finally, slides were cleared in xylene and coverslipped with resinous mounting media.
All Golgi-impregnated sections were examined with an Olympus IX-81 microscope equipped with Cellsens imaging system. The criteria used to select neurons for acquisition and analysis was performed as described previously [32, 33] . Briefly, 
Statistical analysis
All data were presented as the mean ± SEM, and statistical analyses were conducted using Prism 5 software (GraphPad Software Inc., CA). One-way ANOVA or T-test was performed if appropriate. In all cases, P < 0.05 was considered statistically significant.
Results
The activation of CB2R improved the novel object recognition, but not spatial memory impairment in APP/PS1 mice
Results of the NOR test showed that APP/PS1+VEH mice had a significantly
lower RI compared to that of WT+VEH mice (Fig.1A, P<0.05 ). APP/PS1+JWH-015 mice had a significantly higher RI compared to that of APP/PS1+VEH mice (Fig.1A,   P<0 .05), which indicated that JWH-015 treatment can improve novel object recognition memory deficit in APP/PS1 mice.
MWM were performed to examine whether JWH-015 administration affects hippocampus-dependent spatial memory. All mice learned to find the platform without any significant difference in the swimming speed after 5 days training (Fig.1F, P>0 .05).
The APP/PS1+VEH group showed a significantly longer latency and path length to reach the platform, significantly less platform-passing times, and less time spent in the target quarter compared with the WT+VEH group (Fig.1B-E, P<0 .05, respectively).
Representative path tracings of the probe test are shown in Fig.1G . No significant differences were found in escape latency, path length, platform-passing times, and time spent in the target quarter of APP/PS1+JWH mice compared with those of the APP/PS1+VEH mice ( Fig.1B-E , all P>0.05), which indicated JWH-015 treatment had no effects on hippocampus-dependent spatial memory deficit of APP/PS1 mice.
The activation of CB2R had no effects on modifying the plaque deposition in the cortex and Hippocampus of APP/PS1 mice
Aβ proteins and plaque are known to be at the core of the Aβ hypothesis and to some extent relate to cognitive impairment in AD patients and mouse models [34] . To determine the effect of JWH-015 treatment on plaque formation in APP/PS1 mouse brains, we measured the level of plaque deposition in the brain with Congo red staining (Fig 2A-F) . The number of plaque in both the cortex and hippocampus of the APP/PS1+VEH group significantly increased compared to that of the WT+VEH group ( Fig.2A-B , 2E-F). However, there was no statistical difference in plaque number in the cortex and hippocampus between the APP/PS1+VEH group and the APP/PS1+JWH-015 group (Fig.2B-D, 2F -H, P>0.05 respectively). These results suggest JWH-015 treatment did not modify plaque deposition in the cortex and hippocampus of APP/PS1
mice.
The activation of CB2R relieved the activation of microglia in the cortex but not
Hippocampus of APP/PS1 mice
Iba1 is a specific bio-marker for activated microglia cells [35] .
Immunofluorescence assay was performed to examine whether JWH-015 treatment affects microglial activation. Results showed that the immunofluorescence intensity of Iba1 in the APP/PS1+VEH group increased compared with that of the WT+VEH group in both the cortex and hippocampus (Fig.3A-D, P<0.001 ; 3E-H, P<0.001, respectively).
Furthermore, we observed a significant decrease in immunofluorescence intensity of Iba1only in the cortex of APP/PS1+JWH-015 group compared with that of the APP/PS1+VEH group (Fig.3D, P<0.01) . The results suggest that JWH-015 treatment inhibited the activation of microglia in the cortex but not the hippocampus of APP/PS1 transgenic mice.
The activation of CB2R effectively promoted M1 to M2 microglia phenotype conversion in cortex but not hippocampus of APP/PS1 mice
IL-6, TNF-α, and iNOS are generally defined as M1 microglia phenotype biomarkers, while Ym1/2 are often considered as M2 microglia phenotype biomarkers [23, 36] . Real-time PCR was conducted to study the regulatory role of CB2R in the process of microglia phenotype conversion. Results showed that the mRNA levels of M1-type genes (IL-6, TNF-α and iNOS) significantly increased; however, M2-type gene of Ym1/2 in both the hippocampus and cortex of APP/PS1+VEH group was reduced compared with that of the WT+VEH group (All P<0.01). As shown in (Fig. 4A-H) , administration of JWH-015 reversed the mRNA levels of M1-type genes and M2-type genes in the cortex (All P<0.05). Interestingly, the phenomenon of M1 to M2 transformation did not appear in the hippocampus after a long administration JWH-015 period ( Fig.4E-4H , All P>0.05). Taken together, JWH-015 treatment effectively modulated the phenotype conversion of microglia in the cortex but not the hippocampus of APP/PS1 mice.
The activation of CB2R improved the dendritic complexity in the cortex but not hippocampus of APP/PS1 mice
As AD-related cognitive impairments are related to aberrant synaptic plasticity [37] , we next did Golgi staining to investigate the changes of dendritic complexity in the cortex and hippocampus. Results showed a significant decline of total
basal dendritic length, branching points, and dendritic spine density in the cortex in APP/PS1+VEH mice compared with those of WT+VEH mice (Fig.5A-D , 5F-G, All P<0.01). Some dendrites of hippocampal DG granule cells overlapped (Fig. 5E ), so we studied the changes of spine density in each group. In addition, there was a significant decrease in spine density of the hippocampus in APP/PS1+VEH mice compared with that of WT+VEH mice (Fig.5H-I, P<0.01 ). Significant increases of total basal dendritic length, branching points, and spine density were found in the cortex of the APP/PS1+JWH-015 group compared with those of the APP/PS1+VEH mice (All P<0.05). However, no difference was found on spine density in the hippocampus of APP/PS1+VEH group after JWH-015 treatment ( Fig.5H-I ). Thus, JWH-015 treatment effectively reversed the deficit of dendritic complexity in the cortex but not in the hippocampus of APP/PS1 transgenic mice.
Discussion
We found that CB2R activation prevented NOR dysfunction but did not ameliorate spatial cognitive impairment in APP/PS1 transgenic mice. This beneficial and differential role in cognitive ability was associated with reduced microglial immunoreactivity, promoted M1/M2 microglial phenotype conversion, and enhanced dendritic complexity in major relevant brain regions (Fig.6 ).
In contrast to previous researches mentioned in introduction [19] , administration of JWH-015 exerted no beneficial impact on spatial cognitive dysfunction but enhanced novel object recognition memory when compared with APP/PS1+VEH mice. Our conflicting results may be due to the different periods of administration of the CB2R agonist. Additionally, it need to be emphasized that hippocampus-dependent spatial learning and memory is reported to be more vulnerable to neuroinflammation-induced impairment than other cognitive types [38] .
Spatial tasks, like MWM, depend heavily on hippocampal function, while object recognition tests are considered to be associated with the cortex [26, 31] . Therefore, the present study mainly explored the changes of plaque burden and neuroinflammatory parameters in the cortex and hippocampus after JWH-015 treatment. Although reports showed that, in vitro and vivo, the activation of CB2R facilitated the removal of plaque [20, 39] and CB2R deficiency in APP/PS1 mice significantly increased plaque deposition [30] , our results provided strong evidence that plaque deposits both in the cortex and hippocampus were unaltered by CB2R activation, consistent with a previous report [8] . However, Tolón et al. found that CB2R agonist JWH-015 induces the removal of native beta-amyloid from human frozen tissue sections [39] . Aso et al. demonstrated
that JWH-133 increased Aβ clearance in double APP/PS1 transgenic mice, and these effects were more pronounced when administered at the pre-symptomatic (3-month)
rather than the early symptomatic stage (6-month) [20] . Moreover, CB2 deficiency significantly increased soluble Aβ42 and plaque deposition in J20 APP transgenic mice [30] .Our conflicting results may owe to differences in technical means, experimental conditions, and most importantly, disease severity. Therefore, more sensitive and advanced experimental methods are needed to discover the precise role of CB2R on β-amyloid clearance.
Microglia-related neuroinflammation is one of the most striking hallmarks of Alzheimer's disease, and strategies to reduce microglial immunoreactivity or switch M1/M2 phenotype transformation within specific disease stages may increase therapeutic benefit [40] . It was reported that promotion of M1/M2 microglial phenotype conversion through the cAMP/PKA pathway participates in the CB2R-mediated antiinflammatory effects after Germinal matrix hemorrhage induction [23] . Furthermore, the inhibitory effect of CB2R on the activation of microglia also exert a neuroprotective effect in ischemic stroke model mice [9] . Here, activation of CB2R effectively reduced the immunoreactivity of Iba-1 in the cortex but not hippocampus of APP/PS1 mice.
Also, JWH-015 treatment significantly promoted M1/M2 microglia conversion in the cortex but not hippocampus, enhancing mRNA expression of M2 microglia biomarkers Ym1/2 and suppressing mRNA expression of M1 microglia biomarkers (IL-6, iNOS and TNF-α). Our results provide further evidence that CB2R stimulation could promote M1/M2 microglia conversion to exert a neuroprotective role in AD transgenic mice.
It is well established that degeneration of dendritic spine structure, synaptic function and neuronal loss are involved in the pathophysiology of AD and cognitive deficits [37] . Like a previous study [41] , our findings showed that aged APP/PS1 mice
implied a significant decrease in dendritic complexity and spine densities of cortex area and hippocampus, which are associated with the impaired NOR and spatial memory.
Interestingly, CB2R activation remarkably improved the dendritic complexity in the cortex; however, it did not increase the number of dendritic spines in hippocampus.
These findings support the important role of CB2R to improve dendritic complexity in AD progression.
In conclusion, our present study reinforces the therapeutic property of CB2R against the progression of AD. We have demonstrated that the activation of CB2R reversed deficit in NOR memory, without remarkable effects on spatial memory. The underlying mechanism was related to the selective role of CB2R on the microglia- 
Immunofluorescence staining intensity in the hippocampus of different groups. As shown, the expression of Iba1 in APP/PS1+VEH group was increased in both the hippocampus and cortex. Furthermore, there was a significant decrease in immunofluorescence intensity of Iba1 in just the cortex of APP/PS1+JWH-015. Scale bar represents 100 μm. Statistics were calculated by one-way ANOVA, (n=5). *& # means P<0.05. Fig.4 Real-time qPCR was used to detect the mRNA levels of M1 microglia associated biomarkers (IL-6, TNF-α and iNOS) as well as M2 microglia associated marker Ym1/2. The mRNA expression levels of IL-6, TNF-α and iNOS were significantly increased; however, Ym1/2 was significantly decreased in cortex and hippocampus of APP/PS1 mice compared to those of WT littermates. JWH-015 treatment significantly potentiated M1/M2 microglia biomarkers mRNA expression conversion in cortex but not hippocampus of APP/PS1 mice. Statistics were calculated by one-way ANOVA, (n=5). *& # means P<0.05. 
